RxDoctor Payments Data

Jeffrey Feiner, MD

Cardiovascular Disease · Laguna Hills, CANPI 1962594309

Payments from drug & device makers

$29,446in general payments, 2019–2025

Across 1,023 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Infobionic, Inc$7K
  • AOP Health US, LLC$2K
  • Amgen$2K
  • Novartis$2K
  • Biotronik Inc.$1K
  • Boehringer Ingelheim$1K
  • plus $15K from 51 others

What the payments were for

  • Consulting fees$6,62623%
  • Food & beverage$22,47176%
  • Education$3491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,446 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$638,100
Medicare patients
687
Services billed
6,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban339$439,214
ArcalystRilonacept15$351,269
XareltoRivaroxaban119$130,192
Repatha SureclickEvolocumab39$58,991
EntrestoSacubitril/Valsartan46$58,793
JardianceEmpagliflozin31$46,402
NexlizetBempedoic Acid/Ezetimibe29$32,807
MultaqDronedarone Hcl32$31,015
NexletolBempedoic Acid23$24,503
FarxigaDapagliflozin Propanediol24$24,381
MounjaroTirzepatide11$10,881
Olmesartan Medoxomil323$9,549
Ezetimibe226$7,195
Icosapent Ethyl17$6,320
EdarbyclorAzilsartan Med/Chlorthalidone15$6,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$872$439,214339 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$216$351,26915 claims
Johnson & JohnsonXarelto$776$130,192119 claims
NovartisEntresto$1,541$58,79346 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$651$57,31052 claims
Boehringer IngelheimJardiance$1,292$46,40231 claims
Sanofi-aventis U.S. LLCMultaq$879$31,01532 claims
AstraZenecaFarxiga$310$24,38124 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$163$6,27715 claims
ANI Pharmaceuticals, Inc.Valsartan$24$82236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →